Latest Voluntary Administration News

Mineral Commodities Limited has made its CEO role redundant following the appointment of voluntary administrators, signalling deep restructuring ahead.

Epsilon Healthcare Limited has unveiled a comprehensive pre-reinstatement disclosure, highlighting improved financial health and a strategic growth plan focused on operational stability and expansion.

Mineral Commodities Limited and key subsidiaries have entered voluntary administration, with McGrathNicol appointed to explore sale or recapitalisation options. The Skaland Graphite mine operations in Norway remain unaffected, but shares are suspended pending creditor meetings.

EPX Limited has secured Wattwatchers Pty Limited through a Deed of Company Arrangement, backed by a $2.14 million placement and a Share Purchase Plan to raise additional funds. This strategic move enhances EPX’s energy monitoring capabilities and recurring revenue streams.

Epsilon Healthcare reported a 19% revenue increase to $3.4 million for the half year ended June 2025, driven by new client wins and its pharmacy segment launch. However, net losses widened 44% to $2.07 million, reflecting administration and financing costs during its recovery phase.

ChemX Materials Limited has successfully completed its voluntary administration process with creditors approving restructuring agreements for both the parent company and its subsidiary HiPurA Pty Ltd. This marks a significant step towards stabilising operations and returning control to the board.

ChemX Materials Limited has emerged from voluntary administration following a Deed of Company Arrangement, while securing a significant Japanese patent for its HiPurA® High Purity Alumina process.

EPX Limited has submitted a proposal to acquire WattWatchers Pty Limited through a Deed of Company Arrangement, pending creditor approval. The move aims to integrate WattWatchers’ real-time energy monitoring solutions with EPX’s advanced building performance platform.

Pro-Pac Packaging has entered voluntary administration, leading to the redundancy of its CEO and an extended timeline for creditor meetings in Australia and New Zealand.

Epsilon Healthcare has posted its highest-ever quarterly receipts of $2.919 million, reflecting a robust turnaround since exiting voluntary administration in mid-2024. The company’s strategic sale and leaseback deal has also enabled significant debt reduction, setting the stage for sustained growth.

Epsilon Healthcare reports a strong rebound with a 73% revenue increase in the June quarter, driven by contract manufacturing and new pharmacy operations. The company is emerging from restructuring with renewed financial strength and growth prospects.

Epsilon Healthcare has commenced operations of its new pharmacy division and extended a key loan facility, signaling a strategic pivot towards integrated healthcare and financial stability after recent restructuring.